Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Current Leases (2016 - 2025)

Historic Current Leases for Arrowhead Pharmaceuticals (ARWR) over the last 13 years, with Q4 2025 value amounting to $7.5 million.

  • Arrowhead Pharmaceuticals' Current Leases rose 1477.13% to $7.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $7.5 million, marking a year-over-year increase of 1477.13%. This contributed to the annual value of $7.3 million for FY2025, which is 1493.22% up from last year.
  • Arrowhead Pharmaceuticals' Current Leases amounted to $7.5 million in Q4 2025, which was up 1477.13% from $7.3 million recorded in Q3 2025.
  • Arrowhead Pharmaceuticals' Current Leases' 5-year high stood at $10.6 million during Q3 2023, with a 5-year trough of $1.3 million in Q1 2021.
  • For the 5-year period, Arrowhead Pharmaceuticals' Current Leases averaged around $4.6 million, with its median value being $3.2 million (2022).
  • In the last 5 years, Arrowhead Pharmaceuticals' Current Leases skyrocketed by 28051.15% in 2023 and then tumbled by 3996.02% in 2024.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Current Leases (Quarter) stood at $2.8 million in 2021, then decreased by 5.73% to $2.7 million in 2022, then grew by 28.42% to $3.4 million in 2023, then soared by 91.76% to $6.6 million in 2024, then rose by 14.77% to $7.5 million in 2025.
  • Its last three reported values are $7.5 million in Q4 2025, $7.3 million for Q3 2025, and $7.0 million during Q2 2025.